Background
==========

As the basic component of vascular endothelium, endothelial cells are important in various aspects of vascular biology, including barrier function, blood clotting, vasoconstriction, and vasodilation \[[@b1-medscimonit-22-3223]\]. Endothelial dysfunction is a common form of damage in endothelial cells, and generally results from various inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematous \[[@b2-medscimonit-22-3223]\]. It is reported that endothelial dysfunction is a hallmark of vascular diseases, such as coronary artery disease \[[@b3-medscimonit-22-3223]\], hypertension \[[@b4-medscimonit-22-3223]\], and thrombosis \[[@b5-medscimonit-22-3223]\]. Thus, endothelial dysfunction is considered to be a serious problem in clinical practice and urgently needs to be solved.

Endothelium-derived relaxing and contracting factors (EDRF/EDCF) are necessary in the regulation of vascular tone and blood flow distribution of organs \[[@b6-medscimonit-22-3223]\]. Imbalance of these factors leads to endothelial damage and dysfunction \[[@b7-medscimonit-22-3223]\]. Various EDCFs have been identified, including endothelin (ET), urotensin II (UTII), and angiotensin II (Ang II) \[[@b6-medscimonit-22-3223]\]. Among these factors, Ang II is a peptide hormone involved in the renin-angiotensin-aldosterone system, which is extremely important in vasoconstriction and subsequent increased blood pressure \[[@b8-medscimonit-22-3223],[@b9-medscimonit-22-3223]\]. Low concentrations of Ang II *in vivo* maintain normal structure and tension of the blood vessels, while increased Ang II leads to arterial hypertension and even vascular endothelial damage \[[@b10-medscimonit-22-3223]\]. In addition, excessive Ang II is shown to be correlated with enhanced inflammation \[[@b11-medscimonit-22-3223]\], calcium overload \[[@b12-medscimonit-22-3223]\], and serious oxidative stress \[[@b13-medscimonit-22-3223]\], which promote apoptosis of endothelial cells \[[@b14-medscimonit-22-3223]\].

Flavonoid compounds have been reported to protect the cardiovascular system \[[@b15-medscimonit-22-3223]\]. Blueberry anthocyanin (BBA) is a newly discovered flavonoid compound extracted from the fruit of the blueberry plant. BBA has been reported to have anti-inflammatory effects on endothelial cells through the nuclear factor-kappa B pathway, which could prevent chronic inflammations in various diseases \[[@b16-medscimonit-22-3223]\]. Intake of BBA improved vascular function in healthy men in a time- and intake-dependent manner \[[@b17-medscimonit-22-3223]\]. BBA was shown to be efficacious against senescence and light-induced damage in retinal pigment epithelium cells \[[@b18-medscimonit-22-3223]\]. BBA is therefore considered to be effective in protection of endothelial cells *via* its antioxidant and anti-inflammation effects. However, little research has been conducted on the effects of BBA on Ang II-induced endothelial dysfunction and related mechanisms.

Human umbilical vein endothelial cells (HUVECs) are derived from the endothelium of veins in the umbilical cord, and are a popular laboratory model for research on the function and pathology of endothelial cells \[[@b19-medscimonit-22-3223]\]. In the present study, endothelial damage in HUVECs was induced by Ang II, and the effects of BBA on cell viability and apoptosis of HUVECs were evaluated. We also analyzed the related protection mechanism of BBA with Bax and Caspase 3. Our findings may provide new insights for clinical treatment of cardiovascular diseases induced by endothelial dysfunction.

Material and Methods
====================

Cultivation and identification of HUVECs
----------------------------------------

HUVECs (preserved from the pharmacology laboratory in the College of Basic Medical Sciences, Jilin University) were resuscitated by culturing in DMEM medium with high glucose (Gibco, USA) at 37^o^C. These cells were then removed to DMEM medium containing 10% FBS in an incubator (SANYO, Japan) at 37^o^C with 5% CO~2~. When 90% confluence was reached (3--5 days), these cells were digested with 0.25% trypsin and passaged.

Detection of cell viability
---------------------------

HUVECs in logarithmic growth phase were treated by different concentrations of Ang II (Sigma, USA) (10^−9^, 10^−8^, 10^−7^, 10^−6^, 10^−5^, and 10^−4^ mol/L) and BBA (preserved in our laboratory) (80, 40, 20, 10, 5, and 2.5 μg/ml). After 24 h and 48 h of treatment, tetrazolium (MTT) was used to detect the viability of HUVECs. We added 100 μg of MTT (Sigma, USA) into HUVECs seeded at a density of 0.5×10^3^/well in 96-well plates. After 4 h of culturing, 150 μl of DMSO was added into each well, and optical density (OD) at 490 nm was detected by using an ultraviolet spectrophotometer (Bio-Rad, USA).

Detection of apoptosis rate
---------------------------

HUVECs in logarithmic growth phase were randomly divided into the Ang II group (treated with 10^−6^ mol/L Ang II for 2 h) and the Ang II + BBA group (sequentially treated by 10^−6^ mol/L Ang II for 2 h and 20 μg/ml BBA for 24 h). HUVECs without any treatments served as controls. The apoptosis rates of HUVECs in these 3 groups were detected by flow cytometry. Cells were first resuspended in 400 μl 1× binding buffer at a density of 1×10^6^/ml. Then, 5 μl of Annexin V-FITC (Sigma, USA) was added and cells were incubated for 15 min in the dark at room temperature. After 5 min of incubation with 10 μl of Propidium iodide (PI), the fluorescence intensity of cells in each group was detected by flow cytometry (Bio-Rad, USA).

Western blot
------------

Western blot analysis was performed to detect the expression of Bax and Caspase 3 in HUVECs treated by Ang II and Ang II + BBA. Cellular lysates from HUVECs in each group were first isolated by RIPA lysis buffer. Then, total proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) on 12% polyacrylamide gels and transferred to a polyvinylidene fluoride membrane (Millipore). The membrane was blocked with 5% skim milk in TBST for 2 h, and specific diluted primary antibody (anti-Bax, anti-Caspase 3, Sigma, USA) was added. After incubation overnight at 4°C, the membrane was washed with TBST 3 times and incubated for another 2 h at 25°C with FITC-conjugated secondary antibody (Sigma, USA). Finally, the samples were washed with TBST, and semi-quantitative gel images were analyzed by use of an automatic gel imager using Quantity One software (Bio-Rad, USA). During this process, GAPHD was used as the internal control.

Statistical analyses
--------------------

All data are expressed as mean ± standard deviation (SD). Comparison between different groups was performed using the *t-*test (LSD-t), and a *P*-value less than 0.05 was considered to be significantly different. All statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL).

Results
=======

The effects of Ang II and BBA on cell viability of HUVECs
---------------------------------------------------------

To reveal the effects of Ang II and BBA on the HUVECs viability, MTT was conducted. As a result, the cell viability of HUVECs was gradually decreased with increased concentration of Ang II (*P*\<0.05), and obvious inhibition emerged at the concentration of 10^−6^ mol/L (*P*\<0.01). When Ang II concentration reached 10^−4^ mol/L, the inhibition rate of cell viability was 44% at 24 h and 50% at 48 h. Increased treatment time with Ang II were also found to reduce the cell viability of HUVECs (*P*\<0.05). In contrast, BBA at relatively lower concentrations (until a peak concentration of 20.0 μg/ml) significantly elevated the cell viability of HUVECs, while higher concentrations reduced the cell viability (*P*\<0.05). The prolonged intervention time with BBA also reduced the cell viability (*P*\<0.05). However, the cell viability was significantly higher at 48 h than at 24 h at concentrations of 10.0 and 20.0 μg/ml (*P*\<0.05) ([Table 1](#t1-medscimonit-22-3223){ref-type="table"}).

The effects of Ang II and BBA on apoptosis of HUVECs
----------------------------------------------------

To evaluate the effects of Ang II and BBA on HUVECs apoptosis, Ang II (10^−6^ mol/L) and BBA (20.0 μg/ml) at optimum concentration were used to treat HUVECs. As shown in [Figure 1](#f1-medscimonit-22-3223){ref-type="fig"}, the apoptosis rate of HUVECs was significantly increased in the Ang II group (*P*\<0.01). In the Ang II + BBA group, however, the apoptosis rate of HUVECs was significantly reduced, although the rate was still higher than that of the control group (*P*\<0.05) ([Figure 1](#f1-medscimonit-22-3223){ref-type="fig"}).

Changed expression of Bax and Caspase 3 in HUVECs
-------------------------------------------------

To evaluate the anti-apoptosis mechanisms of BBA in HUVECs, the expression level of Bax and Caspase 3 was detected. As shown in [Fig. 2](#f2-medscimonit-22-3223){ref-type="fig"}, Ang II significantly elevated the expression of Bax and Caspase 3 in HUVECs. However, a significantly lower level of Bax and Caspase 3 was found in the Ang II + BBA group compared with that of the Ang II group. The expression level of Bax and Caspase 3 in the Ang II + BBA group was slightly higher than that of the control group ([Figure 2](#f2-medscimonit-22-3223){ref-type="fig"}).

Discussion
==========

Endothelial dysfunction is defined as a systemic pathological state of the endothelium, which is closely related to cardiovascular diseases, including hypertension, hypercholesterolemia, and thrombosis \[[@b20-medscimonit-22-3223]\]. The imbalance of EDRF/EDCF produced by endothelium is considered to be the main cause of endothelial dysfunction, and damage and apoptosis of vascular endothelial cells are always the starting point of these vascular diseases \[[@b21-medscimonit-22-3223]\]. In the present study, EDCF Ang II was used to induce endothelial dysfunction in HUVECs, and an effective protective role of BBA was demonstrated in endothelial cells.

Previous studies have identified relationships between Ang II and endothelial dysfunction \[[@b10-medscimonit-22-3223],[@b22-medscimonit-22-3223],[@b23-medscimonit-22-3223]\]. It has been reported that Ang II is associated with vascular oxidative stress and endothelial dysfunction, which can induce various vascular diseases \[[@b24-medscimonit-22-3223],[@b25-medscimonit-22-3223]\]. Ang II was also shown to be able to progressively induce autophagy, senescence, and apoptosis in HUVECs \[[@b26-medscimonit-22-3223]\]. In the present study, the cell viability of HUVECs was significantly reduced by Ang II in a time- and concentration-dependent manner, and the apoptosis rate was increased by Ang II. Our results agree with previous studies and further illustrate the role of Ang II in endothelial dysfunction. In special mechanisms of this process, Ang II may increase the permeability of blood vessels, induce uptake and oxidation of LDL, promote generation of ROS and inactivation of NO, and finally lead to apoptosis of endothelial cells \[[@b27-medscimonit-22-3223],[@b28-medscimonit-22-3223]\].

BBA, a newly discovered flavonoid compound extracted from blueberries, is effective in protection of endothelial cells \[[@b18-medscimonit-22-3223],[@b29-medscimonit-22-3223]\]. In addition, the antioxidant and anti-inflammation roles of BBA were reported to be able to significantly protect and improve vascular functions \[[@b17-medscimonit-22-3223],[@b30-medscimonit-22-3223]\]. In the present study, BBA at an optimum concentration of 20.0 μg/ml significantly increased the cell viability and reduced the apoptosis rate of HUVECs. This phenomenon is consistent with the special antioxidant and anti-inflammation characteristics of BBA, and illustrate that BBA benefits HUVECs. Our results also demonstrate the significantly decreased expression of Bax and Caspase 3 after intervention with BBA. Bax is a member of the BCL2 family and acts as a pro-apoptotic regulator in a variety of cellular activities \[[@b31-medscimonit-22-3223]\]. In healthy mammalian cells, Bax inactive monomer mainly is distributed in cytosol. When apoptotic signaling emerges, the molecular structure of Bax shifts, then permeability transition pores of mitochondria open *via* interaction with a voltage-dependent anion channel, and the mitochondrial membrane is finally destroyed \[[@b32-medscimonit-22-3223]\]. Activated BAX induces the release of cytochrome c and other pro-apoptotic factors \[[@b33-medscimonit-22-3223]\]. Caspase 3 is a member of the cysteine-aspartic acid protease family and plays a central role in cell apoptosis \[[@b34-medscimonit-22-3223]\]. In apoptotic cells, active Caspase 3 leads to chromatin condensation, nuclear destruction, mRNA degradation, and enzyme inactivation \[[@b35-medscimonit-22-3223]\]. To sum up, the decreased expression of Bax and Caspase 3 indicates that the potential inhibition mechanisms of BBA on apoptosis of HUVECs may be related to Bax- and Caspase 3-dependent pathways.

Conclusions
===========

In conclusion, BBA can recover the reduced cell viability and inhibit apoptosis of HUVECs induced by Ang II through Bax- and Caspase 3-dependent pathways. The ability of BBA to protect vascular endothelial cells illustrates that BBA should be considered as a drug candidate in the treatment of cardiovascular diseases resulting from endothelial dysfunction.
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![Apoptosis of human umbilical vein endothelial cells (HUVECs) treated by 10^−6^ mol/L Ang II and 20.0 μg/ml blueberry anthocyanin (BBA). \*, \*\* Represent significantly different at P\<0.05 and P\<0.01, respectively, when compared with HUVECs without treatment (Control). ^\#^ Represents significantly different at P\<0.05 when compared with Ang II group.](medscimonit-22-3223-g001){#f1-medscimonit-22-3223}

![The expression of Bax and Caspase 3 in human umbilical vein endothelial cells (HUVECs) treated by 10^−6^ mol/L Ang II and 20.0 μg/ml blueberry anthocyanin (BBA). GAPHD was used as internal control.](medscimonit-22-3223-g002){#f2-medscimonit-22-3223}

###### 

Cell viability of human umbilical vein endothelial cells (HUVECs) treated by different concentrations of Ang II and blueberry anthocyanin (BBA) (n=5).

  Concentrations of Ang II   Cell viability (OD/%)                                                   Concentrations of BBA                                                                                                        Cell viability (OD/%)                                                                           
  -------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ----------------------- ----------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  0 mol/L                    1.11±0.03 (100%)                                                        1.09±0.01 (100%)                                                                                                             0 μg/ml                 1.15±0.02 (100%)                                                        1.18±0.02 (100%)
  10^−9^ mol/L               0\. 98±0.02 (90%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}   0.98±0.01 (89%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}     2.5 μg/ml               1.23±0.04 (107%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}    1.23±0.04 (104%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}
  10^−8^ mol/L               0.93±0.01 (84%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}     0.89±0.02 (81%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}     5.0 μg/ml               1.25±0.04 (109%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}    1.26±0.03 (106%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}
  10^−7^ mol/L               0.84±0.02 (76%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}     0.80±0.02 (73%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}     10.0 μg/ml              1.27±0.01 (111%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}    1.32±0.03 (112%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}
  10^−6^ mol/L               0.80±0.01 (73%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}   0.74±0.01 (68%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}   20.0 μg/ml              1.31±0.01 (114%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}    1.39±0.01 (117%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}
  10^−5^ mol/L               0.71±0.03 (66%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}   0.66±0.03 (60%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}   40.0 μg/ml              1.22±0.01 (107%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}    1.19±0.04 (102%)[\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}
  10^−4^ mol/L               0.62±0.03 (56%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}   0.55±0.03 (50%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}   80.0 μg/ml              1.01±0.03 (89%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"}   0.99±0.07 (84%)[\*\*](#tfn1-medscimonit-22-3223){ref-type="table-fn"},[\#](#tfn2-medscimonit-22-3223){ref-type="table-fn"}

Represent significantly different at P\<0.05 and P\<0.01 when compared with HUVECs without treatment, respectively.

Represent significantly different at P\<0.05 when compared with 24 h of treatment.
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